BIO-B

Bio-Rad Laboratories, Inc. [BIO-B] Stock Forecast

Q: What is Bio-Rad Laboratories, Inc. stock symbol ?

Bio-Rad Laboratories, Inc. is a US stock, located in Hercules of Ca and trading under the symbol BIO-B

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BIO-B Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Became profitable this year

BIO-B has more than 13 years of cash runway (161 months)

Earnings are expected to fall -100% next year

An RSI reading of 30 or below indicates an oversold or undervalued condition.

In the News

BIO-B Financial details

Company Rating

Buy

Market Cap

9.44B

Income

-637.32M

Revenue

2.67B

Book val./share

303.6

Cash/share

56.02

Dividend

Dividend %

Employees

8.03K

Optionable

Shortable

Yes

Earnings

25 Apr 2024

P/E

-58.05

Forward P/E

PEG

7.05

P/S

3.41

P/B

1.1

P/C

P/FCF

41.62

Quick Ratio

3.98

Current Ratio

5.64

Debt / Equity

0.14

LT Debt / Equity

0.14

EPS (TTM)

-21.46

EPS next Y

EPS next Q

EPS this Y

-82.08%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

2.93%

Revenue Q/Q

7.76%

EPS Q/Q

232.88%

SMA20

-1.88%

SMA50

0.64%

SMA100

Inst Own

0.01%

Inst Trans

ROA

-1%

ROE

-2%

ROC

0.04%

Gross Margin

54%

Oper. Margin

15%

Profit Margin

-6%

Payout

-51981%

Shs Outstand

Shs Float

Target Price

52W Range

271.0-467.95

52W High

-40.06%

52W Low

+3.29%

RSI

Rel Volume

1.76

Avg Volume

267

Volume

470

Perf Week

-15.74%

Perf Month

-11.78%

Perf Quarter

Perf Half Y

-21.17%

Beta

0.88

Volatility

26.2%, 18.66%

Prev Close

Price

279.91

Change

-0.58%

BIO-B Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	77.46	85.52	97.97	94.08	91.45
Net income per share	58.93	128.13	142.61	-121.79	-21.82
Operating cash flow per share	15.34	19.33	22.01	6.53	12.84
Free cash flow per share	12.04	16	17.96	2.7	7.47
Cash per share	37.54	33.48	29.35	60.31	55.22
Book value per share	192.84	331.9	458.15	322.82	299.26
Tangible book value per share	179.12	315.39	438	298.02	274.13
Share holders equity per share	192.84	331.9	458.15	322.82	299.26
Interest debt per share	15.52	1.21	0.42	41.51	43.83
Market cap	11.04B	17.35B	22.54B	12.52B	9.43B
Enterprise value	10.82B	16.7B	22.08B	13.29B	10.43B
P/E ratio	6.28	4.55	5.3	-3.45	-14.8
Price to sales ratio	4.78	6.82	7.71	4.47	3.53
POCF ratio	24.12	30.16	34.33	64.41	25.15
PFCF ratio	30.73	36.42	42.07	155.99	43.21
P/B Ratio	1.92	1.76	1.65	1.3	1.08
PTB ratio	1.92	1.76	1.65	1.3	1.08
EV to sales	4.68	6.56	7.55	4.74	3.91
Enterprise value over EBITDA	27.75	29.12	33.97	20	18.11
EV to operating cash flow	23.63	29.04	33.63	68.34	27.83
EV to free cash flow	30.11	35.06	41.22	165.5	47.8
Earnings yield	0.16	0.22	0.19	-0.29	-0.07
Free cash flow yield	0.03	0.03	0.02	0.01	0.02
Debt to equity	0.08	0	0	0.12	0.14
Debt to assets	0.05	0	0	0.09	0.1
Net debt to EBITDA	-0.57	-1.13	-0.71	1.15	1.74
Current ratio	2.41	3.39	2.92	5.55	5.83
Interest coverage	9.81	18.8	315.56	12.66	7.76
Income quality	0.26	0.15	0.15	-0.05	-0.59
Dividend Yield	0.35	0	1.57	5.44	10.61
Payout ratio	2.18	0.01	8.29	-18.8	-157.06
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.09	0.09	0.09	0.09	0.08
Intangibles to total assets	0.05	0.04	0.03	0.05	0.06
Capex to operating cash flow	-0.22	-0.17	-0.18	-0.59	-0.42
Capex to revenue	-0.04	-0.04	-0.04	-0.04	-0.06
Capex to depreciation	-0.73	-0.72	-0.9	-0.83	-0.81
Stock based compensation to revenue	0.02	0.02	0.02	0.02	0.02
Graham number	505.67	978.19	1.21K	940.55	383.3
ROIC	0.03	0.03	0.03	0.03	0.03
Return on tangible assets	0.23	0.31	0.25	-0.28	-0.06
Graham Net	-18.83	-49.39	-88.14	-45.65	-40.37
Working capital	1.27B	1.51B	1.31B	2.59B	2.53B
Tangible asset value	5.35B	9.39B	13.07B	8.88B	8.01B
Net current asset value	-73.65M	-952.84M	-2.12B	-728.44M	-509.61M
Invested capital	0.08	0	0	0.12	0.14
Average receivables	392.91M	406.05M	421.48M	459.09M	497.78M
Average payables	275.78M	324.71M	390.63M	374.38M	236.33M
Average inventory	569.17M	588.13M	597.25M	645.78M	749.92M
Days sales outstanding	62	60.14	52.9	64.43	68.45
Days payables outstanding	99.36	119.38	119.28	97.49	42.04
Days of inventory on hand	191.73	205.02	162.94	212.61	229.76
Receivables turnover	5.89	6.07	6.9	5.67	5.33
Payables turnover	3.67	3.06	3.06	3.74	8.68
Inventory turnover	1.9	1.78	2.24	1.72	1.59
ROE	0.31	0.39	0.31	-0.38	-0.07
Capex per share	-3.3	-3.32	-4.05	-3.83	-5.36

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	24.6	22.87	23.2	21.72	23.66
Net income per share	28.08	2.33	-39.59	3.65	12.15
Operating cash flow per share	3.05	3.32	3.34	3.36	2.81
Free cash flow per share	1.47	2.11	2.16	1.84	1.35
Cash per share	60.51	62.75	58.87	60.63	56.02
Book value per share	323.93	329.9	287.75	289.2	303.6
Tangible book value per share	299.05	305.05	262.53	264.42	278.1
Share holders equity per share	323.93	329.9	287.75	289.2	303.6
Interest debt per share	40.76	40.91	41.26	41.63	43.18
Market cap	12.48B	14.18B	11.13B	10.43B	9.3B
Enterprise value	13.25B	14.91B	11.94B	11.17B	10.3B
P/E ratio	3.74	51.39	-2.39	24.54	6.65
Price to sales ratio	17.09	20.95	16.34	16.5	13.65
POCF ratio	138.04	144.49	113.49	106.76	114.71
PFCF ratio	287.01	227.22	175.46	194.47	239.59
P/B Ratio	1.3	1.45	1.32	1.24	1.06
PTB ratio	1.3	1.45	1.32	1.24	1.06
EV to sales	18.14	22.03	17.53	17.68	15.12
Enterprise value over EBITDA	82.36	100.8	84.1	75.13	68.3
EV to operating cash flow	146.49	151.97	121.73	114.35	127.07
EV to free cash flow	304.58	238.99	188.22	208.3	265.41
Earnings yield	0.07	0	-0.1	0.01	0.04
Free cash flow yield	0	0	0.01	0.01	0
Debt to equity	0.12	0.12	0.14	0.14	0.14
Debt to assets	0.09	0.09	0.1	0.1	0.1
Net debt to EBITDA	4.75	4.96	5.7	4.98	6.64
Current ratio	5.55	5.56	5.39	5.64	5.83
Interest coverage	10.16	9.11	7.26	7.34	7.91
Income quality	0.11	1.42	-0.08	0.92	0.23
Dividend Yield	3.8	1.03	0.02	0	9.19
Payout ratio	56.91	212.61	-0.17	0.04	244.32
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.09	0.11	0.1	0.07	0.09
Intangibles to total assets	0.05	0.05	0.06	0.06	0.06
Capex to operating cash flow	-0.52	-0.36	-0.35	-0.45	-0.52
Capex to revenue	-0.06	-0.05	-0.05	-0.07	-0.06
Capex to depreciation	-1.17	-1	-0.97	-1.18	-0.8
Stock based compensation to revenue	0.02	0.02	0.02	0.03	0.02
Graham number	452.39	131.51	506.3	154.14	288.04
ROIC	0.01	0.01	0.01	0.01	0.01
Return on tangible assets	0.07	0.01	-0.1	0.01	0.03
Graham Net	-45.8	-43.81	-35.64	-33.82	-40.95
Working capital	2.59B	2.69B	2.56B	2.59B	2.53B
Tangible asset value	8.88B	9.03B	7.71B	7.7B	8.01B
Net current asset value	-728.44M	-626.45M	-392.47M	-332.98M	-509.61M
Invested capital	0.12	0.12	0.14	0.14	0.14
Average receivables	463.47M	496.46M	494.92M	474.49M	479.16M
Average payables	332.52M	332.36M	319.57M	285.52M	204.82M
Average inventory	702.58M	736.13M	764.77M	776.21M	778.17M
Days sales outstanding	60.96	66.26	64.96	65.12	66.18
Days payables outstanding	89.09	95.86	85.94	81	40.77
Days of inventory on hand	194.3	215.52	219.36	235.54	222.8
Receivables turnover	1.48	1.36	1.39	1.38	1.36
Payables turnover	1.01	0.94	1.05	1.11	2.21
Inventory turnover	0.46	0.42	0.41	0.38	0.4
ROE	0.09	0.01	-0.14	0.01	0.04
Capex per share	-1.58	-1.21	-1.18	-1.51	-1.47

BIO-B Frequently Asked Questions

What is Bio-Rad Laboratories, Inc. stock symbol ?

Bio-Rad Laboratories, Inc. is a US stock , located in Hercules of Ca and trading under the symbol BIO-B

What is Bio-Rad Laboratories, Inc. stock quote today ?

Bio-Rad Laboratories, Inc. stock price is $279.91 today.

Is Bio-Rad Laboratories, Inc. stock public?

Yes, Bio-Rad Laboratories, Inc. is a publicly traded company.

Something similar

Top by Market Cap

VTI

Company Profile

Volume Average 267
Market Capitalization 9.44B
Employee 8.03K
CEO Mr. Norman D. Schwartz
Headquarters Hercules,CA,US
IPO Date 1999-09-21
Website https://www.bio-rad.com

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.